Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing.
CRC screening
FIT
SEPT9
adherence
blood-based screening
colonoscopy
colorectal cancer
stool-based screening
Journal
American health & drug benefits
ISSN: 1942-2962
Titre abrégé: Am Health Drug Benefits
Pays: United States
ID NLM: 101479877
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
ppublish
Résumé
Screening for colorectal cancer (CRC) is effective at reducing mortality, but nearly 35% of eligible patients do not get screened. New noninvasive screening methods may help increase CRC screening participation. Current CRC screening methods include blood-based screening with methylated Septin 9 ( To estimate the cost and clinical implications to health plans, including the clinical and fiscal implications of the use of blood-based screening with We designed a simulation model to estimate the 3-year clinical and economic impacts for noninvasive screening scenarios and for no screening in the screening-nonadherent population. Clinical inputs were derived from In the health plan population, 232,000 members aged 50 to 64 years were eligible for screening, of whom 81,200 (35%) were unscreened. The number of cases of CRC that were detected was similar for each screening scenario, including 221 for Our simulation model suggests that similar clinical detection rates are achievable with the 3 noninvasive blood- and stool-based screening methods. These results support a role for blood- and stool-based screening to increase participation in CRC screening.
Sections du résumé
BACKGROUND
BACKGROUND
Screening for colorectal cancer (CRC) is effective at reducing mortality, but nearly 35% of eligible patients do not get screened. New noninvasive screening methods may help increase CRC screening participation. Current CRC screening methods include blood-based screening with methylated Septin 9 (
OBJECTIVES
OBJECTIVE
To estimate the cost and clinical implications to health plans, including the clinical and fiscal implications of the use of blood-based screening with
METHODS
METHODS
We designed a simulation model to estimate the 3-year clinical and economic impacts for noninvasive screening scenarios and for no screening in the screening-nonadherent population. Clinical inputs were derived from
RESULTS
RESULTS
In the health plan population, 232,000 members aged 50 to 64 years were eligible for screening, of whom 81,200 (35%) were unscreened. The number of cases of CRC that were detected was similar for each screening scenario, including 221 for
CONCLUSIONS
CONCLUSIONS
Our simulation model suggests that similar clinical detection rates are achievable with the 3 noninvasive blood- and stool-based screening methods. These results support a role for blood- and stool-based screening to increase participation in CRC screening.
Types de publication
Journal Article
Langues
eng
Pagination
256-262Informations de copyright
Copyright © 2019 by Engage Healthcare Communications, LLC.
Références
Am J Gastroenterol. 2014 Oct;109(10):1513-25
pubmed: 24980877
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
MMWR Morb Mortal Wkly Rep. 2013 Nov 8;62(44):881-8
pubmed: 24196665
Am J Manag Care. 2015 Jul 01;21(7):e430-8
pubmed: 26295271
Am J Prev Med. 2016 Feb;50(2):e54-61
pubmed: 26362405
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
N Engl J Med. 2014 Apr 3;370(14):1287-97
pubmed: 24645800
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Clin Chem. 2014 Sep;60(9):1183-91
pubmed: 24938752
Am J Gastroenterol. 2017 Feb;112(2):375-382
pubmed: 28154400
JAMA. 2016 Jun 21;315(23):2595-609
pubmed: 27305518
PLoS One. 2014 Jun 05;9(6):e98238
pubmed: 24901436
Ann Intern Med. 2016 Apr 5;164(7):456-63
pubmed: 26811150
Gastroenterology. 2019 Jan;156(1):63-74.e6
pubmed: 30268788
J Natl Cancer Inst. 2008 May 7;100(9):630-41
pubmed: 18445825
Gut. 2014 Feb;63(2):317-25
pubmed: 23408352
Am J Gastroenterol. 2016 Nov;111(11):1630-1636
pubmed: 27481306
Cancer. 2015 Jul 1;121(13):2281-5
pubmed: 25763558
BMC Gastroenterol. 2014 Oct 17;14:183
pubmed: 25326034
Cancer. 2006 Sep 1;107(5 Suppl):1142-52
pubmed: 16835912